GLP-1 / Metabolic

Mazdutide

Also known as: IBI362

Mazdutide is a dual GLP-1 / glucagon receptor agonist licensed from Eli Lilly to Innovent Biologics for Greater China. Approved by China's NMPA in June 2025 for chronic weight management and in September 2025 for glycemic control in type 2 diabetes; NOT FDA-approved in the US.

Vendors carrying Mazdutide

0 listings, ranked by trust score

Each row is a (vendor, peptide) pair. Click through for the listing detail, the vendor's full trust profile, and any COAs they've published.

No vendors carrying this peptide are indexed yet.